GleamWall
中文EN

FHTX Foghorn Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1822462 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY357.3%
TTM net income YoY113.1%
TTM EPS YoY107.9%
Revenue 3-yr CAGR51.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin2.1%
Net margin8.4%
FCF margin-74.6%
EBITDA margin3.4%

Returns

ROE—
ROA4.8%
ROIC (approx.)—
Asset turnover0.57x

Leverage & solvency

Liabilities / assets107.4%
Debt / equity—
Current ratio4.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-8.88x
Accruals ratio47.0%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$83.54M$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M
R&D expense$18.84M$18.52M$18.26M$22.05M$20.00M$21.79M$21.63M$20.51M
SG&A expense$5.80M$6.35M$6.58M$6.80M$6.65M$6.86M$7.24M$6.35M
Operating income$56.64M-$8.80M-$21.57M-$23.88M-$18.50M-$21.10M-$22.91M-$24.00M
Pretax income———————-$19.50M
Income tax———————$0
Net income$58.15M-$7.19M-$19.88M-$21.66M-$15.85M-$17.94M-$18.83M-$19.50M
EBITDA$56.84M-$8.61M-$21.34M-$23.08M-$17.60M-$20.20M-$22.09M-$23.24M
EPS (basic)0.81-0.10-0.29—-0.25-0.28-0.30—
EPS (diluted)0.80-0.10-0.29—-0.25-0.28-0.30—
Weighted avg. shares (diluted)72.59M70.63M69.54M—63.03M62.98M62.85M—
Balance sheet
Cash & equivalents$80.30M$68.08M$87.66M$80.88M$89.33M$72.57M$61.03M$57.16M
Current assets$158.31M$170.05M$188.06M$163.24M$184.12M$203.84M$225.42M$249.60M
PP&E, net$1.29M$1.50M$1.71M$1.92M$8.66M$9.51M$10.35M$9.96M
Total assets$190.95M$203.39M$222.17M$198.10M$204.96M$226.24M$258.69M$283.98M
Current liabilities$37.31M$50.58M$64.40M$59.74M$85.09M$77.79M$71.31M$66.99M
Total liabilities$205.04M$284.43M$298.57M$306.60M$294.62M$302.89M$320.34M$329.51M
Shareholders' equity-$14.08M-$81.04M-$76.41M-$108.50M-$89.66M-$76.66M-$61.65M-$45.53M
Shares outstanding59.96M58.71M58.71M56.66M56.54M55.80M55.72M55.59M
Cash flow statement
Operating cash flow-$18.24M-$17.84M-$25.27M-$22.27M-$18.86M-$21.00M-$23.97M-$24.52M
Capital expenditure$7,000$50,000$0$0$0$22,000$28,000$479,000
Free cash flow-$18.25M-$17.89M-$25.27M-$22.27M-$18.86M-$21.02M-$24.00M-$25.00M
Investing cash flow$24.19M-$2.97M-$17.72M$13.23M$35.57M$33.83M$29.40M$22.29M
Financing cash flow$6.28M-$22,000$49.77M$581,000$49,000$254,000$139,000$4,000
Depreciation & amortization$200,000$200,000$238,000$802,000$900,000$900,000$827,000$761,000
Stock-based compensation$2.52M$2.55M$2.38M$2.24M$2.73M$2.73M$2.69M$2.48M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.